Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG’s (OTC:RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.

• Olema Pharmaceuticals stock is feeling bearish pressure. Why are OLMA shares down?

The study did not meet its primary objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.

The study showed a numerical improvement.

Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist.

Investors should note that Olema’s lead product candidate, Palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and SERD.

Palazestrant is undergoing several clinical trials for breast cancer in collaboration with Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS).

In November 2025, Olema Pharmaceuticals surged over 200% after Roche released phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer.

OLMA’s Bearish Trend: Below SMA Indicators

Currently, the stock is trading 26.2% below its 20-day simple moving average (SMA) and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term.

Over the past 12 months, shares have increased by 294.05%, reflecting strong long-term performance, but they are currently positioned closer to their 52-week lows than highs.

The RSI is at 34.36, which is considered neutral territory, while the MACD shows a value of -0.6379, below its signal line at -0.5304, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term outlook.

  • Key Resistance: $24
  • Key Support: $17

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $37.33. Recent analyst moves include:

  • HC Wainwright & Co.: Maintained with Buy (target raised to $38 on March 9)
  • Stifel: Initiated with Buy (target $48 on Feb. 11)
  • UBS: Initiated with Buy (target $45 on Jan. 7)
  • Piper Sandler: Initiated with Overweight on Jan. 7)

OLMA Price Action: Olema Pharmaceuticals shares were down 20.46% at $17.14 at the time of publication on Monday, according to Benzinga Pro data.

Image via Shutterstock